Skip to main content

Research News

  • There has been a 16 per cent increase in daily generation of bio-medical waste in 2012-13 as against a marginal increase of 0.33 per cent the year ago, Lok Sabha was informed. Karnataka was the highest producer of bio-waste at 83,614 kg per day, followed by Maharashtra, which produced 65,660 kg of bio-wastes every day.

  • In the United States every year nearly 90,000 women are diagnosed with some gynecological cancer. These include cancer of the cervix, uterus, ovaries, vagina, and vulva. These women undergo treatments including radiation, chemotherapy and surgery. A University of Colorado Cancer Center study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015  has shown sexual dysfunction in women following gynecologic cancer treatment. The study shows decreased sexual activity in women following treatment for gynecologic cancers, down from 6.1-6.8 times per month before treatment to 2.6-4.9 times per month after treatment.

    [adsense:336x280:8701650588]

  • Merozyne Therapeutics AB has started a project goal to develop a pharmaceutical treatment against laminin alpha2 chain-deficient congenital muscular dystrophy (MDC1A) by exploiting the unique research conducted by Prof. Madeleine Durbeej-Hjalt and Dr Virginie Carmignac at Lund University.

  • Biocartis and Fast-track diagnostics, have entered into a strategic collaboration to develop a range of multiplex infectious disease tests to run on the Biocartis Idylla system. As part of the collaboration, tests from Fast-track diagnostics’ comprehensive infectious disease menu will be developed for use on Biocartis’ innovative molecular diagnostics (MDx) platform, Idylla. Idylla is a fully-automated MDx system that delivers accurate, rapid tests in virtually any setting, from virtually any biological sample type, and without the need for pre-processing or specialist training.

  • Lemtrada (alemtuzumab), is new drug developed for treatment of Multiple Sclerosis (MS) reduces the relapse rates. Recently, Samuel F. Hunter, MD, PhD, President of the Advanced Neurosciences Institute in Franklin, Tennessee, presented a paper at the 2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers in Indianapolis, Indiana on outcomes in patients with relapsing multiple sclerosis treated with Lemtrada (alemtuzumab).

  • The Indian Council of Medical Research (ICMR) will soon start research on stillbirth to identify and understand the local causes and risk factors from the medical and sociological perspective. ICMR's initiative on stillbirth is significant as nearly 3 million third-trimester stillbirths occurring worldwide each year and 98 per cent of these occur in low-income and middle-income countries.  More than 1 million stillbirths occur in the intrapartum period, which can largely be prevented. The cause of stillbirth remains unidentified in India.

  • Using a partial synthetic process, by extracting trabectedin or ET-743, a compound found in marine invertebrate., scientists are producing a natural cancer drug. They are isolating the genetic blueprint of the ET-743's producer by using advanced sequencing techniques. The insights will make it possible for scientists to culture the bacteria in the laboratory without its host.

Subscribe to Research News